Getein Biotech(603387)2024-04-29 12:49Financial Performance - In 2023, the company achieved a net profit of RMB 284,080,449.03, with a net profit attributable to shareholders of RMB 279,771,914.08, representing a profit distribution ratio of 36.25%[5][7]. - The company's operating revenue for 2023 was ¥1,369,162,256.52, a decrease of 24.85% compared to ¥1,821,860,703.15 in 2022[22]. - Net profit attributable to shareholders decreased by 43.92% to ¥279,771,914.08 from ¥498,909,980.40 in the previous year[24]. - Basic and diluted earnings per share fell to ¥0.55, down 43.88% from ¥0.98 in 2022[23]. - The cash flow from operating activities decreased by 31% to ¥333,220,661.81, compared to ¥482,957,526.77 in 2022[24]. - The company's total assets increased by 2.52% to ¥3,771,626,052.94 at the end of 2023, up from ¥3,678,885,572.13 at the end of 2022[22]. - The weighted average return on equity decreased by 10.59 percentage points to 11.17% from 21.76% in 2022[23]. - The net profit after deducting non-recurring gains and losses was ¥241,487,200.13, a decrease of 47.68% from ¥461,538,014.58 in 2022[22]. - The company's total distributable profit for 2023 was RMB 1,508,000,016.03, after accounting for the retained earnings and cash dividends paid in 2022[5]. - The company's total distributable profit for the parent company in 2023 was RMB 1,240,680,112.38, after accounting for retained earnings and cash dividends[5]. Dividend Distribution - The company proposed a cash dividend of RMB 1 per 10 shares, amounting to a total cash dividend distribution of RMB 50,715,351.70 based on the total share capital of 507,153,517 shares[6]. - The total cash dividend amount for the year is CNY 101,430,703.40, accounting for 36.25% of the net profit attributable to ordinary shareholders in the consolidated financial statements[175]. - The company plans to distribute at least 30% of the average annual distributable profit over the last three years as cash dividends[167]. - The company has a cash dividend policy that stipulates a minimum of 10% of the distributable profit will be distributed as cash dividends if there are no major investment plans or cash expenditures[167]. Research and Development - The company plans to continue its focus on research and development of new products and technologies to enhance market competitiveness[8]. - R&D investment for the reporting period was 266 million yuan, accounting for 19.40% of the operating revenue[38]. - The company has established eight major technology platforms in the IVD field, expanding its product range from low-throughput to high-throughput solutions[82]. - The company aims to enhance its R&D capabilities and product lineup, focusing on a "production generation, R&D generation, and reserve generation" strategy for innovation[122]. - The company plans to increase R&D investment in high-speed fully automated immunoassay analyzers and nucleic acid POCT products, aiming to maintain its leading position in the POCT market[122]. Market Expansion - The company is expanding its overseas market presence, focusing on regions such as Europe, Asia, and Latin America, with a strategy to promote its products in local markets[39]. - The company has established wholly-owned subsidiaries in Hong Kong, Singapore, and Germany, with plans to set up offices in Southeast Asia, South Asia, and Africa in 2024 to enhance local market penetration[123]. - The company aims to expand its market reach from grassroots medical institutions to higher-tier hospitals and international markets, establishing a multi-channel sales system[54]. - The company is set to focus on three major product line strategies: multi-level POCT products, innovative production line products, and nucleic acid POCT strategy[120]. Product Development - The company launched the MAGICL 6000i, which has a testing speed of 200T/h, enhancing its competitive position in the small chemiluminescence market[35]. - The company launched 15 new testing kits, including 1 for inflammation, 3 for cardiovascular diseases, 2 for rheumatology, and various others, utilizing fluorescence immunochromatography and chemiluminescence methods[56]. - The company has registered 74 new reagent products in 2023, including 14 in the POCT field and 23 in the chemiluminescence field, reflecting ongoing product development and market expansion efforts[55]. - The company is focusing on home testing reagents for disease screening and management, targeting common diseases such as diabetes, hypertension, and heart disease[76]. Compliance and Governance - The company's financial report has been audited by Gongzheng Tianye Accounting Firm, which issued an unqualified opinion with emphasis on certain matters[4]. - The company maintains independent financial operations with a dedicated finance department and a separate accounting system, ensuring compliance with regulations[135]. - The company has a comprehensive internal control system covering various financial management aspects, including related party transactions and external guarantees[135]. - The company has not faced any penalties from securities regulatory agencies in the past three years, indicating compliance with regulations[153]. Environmental Responsibility - The company has achieved compliance with the wastewater discharge standards, with TP and NH3-N levels meeting the B grade standards of GB/T31962-2015[185]. - The company has implemented a rainwater separation system, with all rainwater being collected and directed to the municipal rainwater drainage system[185]. - The company reported a total investment of CNY 1.32 million in social responsibility initiatives, including donations to various charitable foundations[190]. - The company has taken measures to reduce carbon emissions, focusing on energy-saving practices and the use of environmentally friendly equipment[190]. Risk Management - The company has outlined various risk factors that may impact its future development strategies and operational goals, with corresponding mitigation measures[9]. - The company has implemented risk control measures for foreign exchange hedging, including only engaging with large banks for transactions[114]. - The company faces risks from industry policy changes and price pressures due to centralized procurement, which could impact its operations if not addressed[126]. Shareholder Engagement - The company has established effective communication channels with investors to ensure equal treatment and transparency[132]. - The company has a complete decision-making process for profit distribution, ensuring the involvement of independent directors and minority shareholders[172]. - The company plans to implement a three-year shareholder return plan from 2023 to 2025, emphasizing commitment to shareholder value[158].